ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.79515
-0.73%
Brent Oil
83.98
0.50%
Bitcoin
62,401.90
1.98%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Zentalis Pharmaceuticals Inc (ZNTL)

  7. Zentalis Pharmaceuticals Inc (ZNTL) Noticias

ZNTL Zentalis Pharmaceuticals Inc

12.52
0.09 (0.72%)
Fuera de horario
Última actualización: 15:07:48
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Zentalis Pharmaceuticals Inc ZNTL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.09 0.72% 12.52 15:07:48
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
12.45 12.22 12.857 12.55 12.43
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/5/202406:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202406:03EDGAR2Form 8-K - Current report
07/5/202406:00GLOBEZentalis Pharmaceuticals Reports First Quarter 2024..
01/5/202416:30GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
02/4/202415:05GLOBEZentalis Pharmaceuticals to Highlight Preclinical Data..
01/4/202416:30GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
01/3/202417:00GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
29/2/202416:20EDGAR2Form S-8 - Securities to be offered to employees in employee..
29/2/202416:14EDGAR2Form S-3ASR - Automatic shelf registration statement of..
28/2/202406:00GLOBEZentalis Pharmaceuticals to Participate in Upcoming Investor..
27/2/202406:08EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202406:04EDGAR2Form 8-K - Current report
27/2/202406:00GLOBEZentalis Pharmaceuticals Reports Full Year 2023 Financial..
15/2/202415:12EDGAR2Form 8-K - Current report
13/2/202418:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202406:00GLOBEZentalis Pharmaceuticals to Participate in the Oppenheimer..
12/2/202419:25EDGAR2Form 144 - Report of proposed sale of securities
12/2/202419:25EDGAR2Form 144 - Report of proposed sale of securities
12/2/202419:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202420:29EDGAR2Form 144 - Report of proposed sale of securities
02/2/202420:29EDGAR2Form 144 - Report of proposed sale of securities
02/2/202420:28EDGAR2Form 144 - Report of proposed sale of securities
02/2/202420:27EDGAR2Form 144 - Report of proposed sale of securities
02/2/202420:26EDGAR2Form 144 - Report of proposed sale of securities
01/2/202416:00GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
25/1/202406:03EDGAR2Form 8-K - Current report
25/1/202406:00GLOBEZentalis Pharmaceuticals Strengthens Management Team with..
08/1/202406:03EDGAR2Form 8-K - Current report
08/1/202406:00BWImmunome Exclusively Licenses Zentalis ROR1 Antibody-Drug..
03/1/202419:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202419:19EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202415:49GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
21/12/202316:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202316:39GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
13/11/202316:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202316:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202306:00GLOBEZentalis to Participate in Investor Call Focused on Ovarian..
06/11/202308:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202308:04EDGAR2Form 8-K - Current report
06/11/202306:18GLOBEZentalis Pharmaceuticals Reports Third Quarter 2023..
01/11/202315:52GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
06/10/202318:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202318:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202318:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202316:00EDGAR2Form 8-K - Current report
04/10/202319:28EDGAR2Form 144 - Report of proposed sale of securities

Su Consulta Reciente

NASDAQ
ZNTL
Zentalis Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados